AstraZeneca sells up to $4bn of stock, raising eyebrows
Astra Zeneca is selling up to half its stock in an attempt to reduce a massive market-wide sale of the company’s generic drug business.The drugmaker is raising $4.3bn in the latest round of financing and plans to raise more than $8bn over the next 12 months, according to an investor presentation published Thursday.The company also…